A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

(2013) T. Heise et al.   DIABETES OBESITY & METABOLISM

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

(2012) J. Rosenstock et al.   DIABETES CARE

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects

(2012) Ele Ferrannini et al.   Nature Reviews Endocrinology

Learning From Glycosuria: FIG. 1.

(2011) Ele Ferrannini   DIABETES

Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats

(2011) L. Thomas et al.   DIABETES OBESITY & METABOLISM

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans

(2011) James F. List et al.   KIDNEY INTERNATIONAL

SGLT2 inhibition — a novel strategy for diabetes treatment

(2010) Edward C. Chao et al.   NATURE REVIEWS DRUG DISCOVERY

Treatment approach and HbA1ccontrol among US adults with type 2 diabetes: NHANES 1999–2004

(2009) Allison Hedley Dodd et al.   CURRENT MEDICAL RESEARCH AND OPINION